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Introduction
Malaria is caused by a parasitic protozoan transmitted by Anophe-
les sp. mosquitos. The pathology’s symptoms in the human host 
are caused by a particular life stage of the parasite, the erythrocyt-
ic stage, that involves the invasion and destruction of infected red 
blood cells (iRBCs). This process causes fever, chills, and anemia 
and can lead to severe symptoms, as in the case of cerebral malar-
ia, such as coma and seizures, leading to the death of the patient. 
This pathology still urgently needs scientific investigation due to 
the resistance of parasites to available medicines. Indeed, the emer-
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AbsTr ACT
Poupartone B is an alkyl cyclohexenone derivative isolated from 
Poupartia borbonica. This compound demonstrated promising 
antimalarial activity (IC50  <  1 µg/mL), however, it was not de-
void of toxicity. Thus, to reduce the adverse side effects of this 
natural bioactive molecule, a delivery strategy involving a na-
nostructure was formulated. Additionally, poupartone B-load-
ed liposomes were coated with heparin, a glycosaminoglycan 
that is known to target proteins on the surface of Plasmodium 
falciparum-infected red blood cells. The quantification of the 
compound in the formulation was performed by HPLC-DAD, 
while heparin was quantitated by 1H NMR spectroscopy. The 
liposomes’ antiplasmodial activity was tested on artemisinin-
resistant P. falciparum isolate, and toxicity was evaluated on 
human HeLa cells and zebrafish embryos. Throughout this re-
search, the formulation demonstrated higher antiplasmodial 
activities against both P. falciparum strains and a significant 
decrease of in vitro toxicity. The formulation improved the se-
lectivity index 2 times in vitro and proved to be 3 times less 
toxic than the compound alone in the zebrafish embryo acute 
toxicity test. Hence, the use of this strategy to deliver natural 
products in Plasmodium-infected cells, particularly those with 
a narrow therapeutic margin, is proposed.
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gence of artemisinin-resistant strains is a threat to eradication pol-
icies and reminds the community of the development of chloro-
quine resistance that happened in the 1960s in Asia [1], and which 
has since then spread to Africa, making the use of the compound 
more and more difficult.
According to the last World Malaria Report published by the World 
Health Organization (WHO), an estimated 216 million cases of ma-
laria occurred in 2016, while 211 million cases were reported in 2015. 
This pathology is evidence of a high burden, having killed 438 000 
people in 2015 and 445 000 in 2016, mostly children under 5 years. 
For the first time in the last 10 years, a substantial increase in inci-
dence rates occurred worldwide, of which around 99 % of the cases 
can be attributed to Plasmodium falciparum[2]. According to the 
WHO, the emergence of parasite resistance to antimalarial medi-
cines and the lack of a sustainable and predictable international and 
domestic funding are involved in the upsurge of malaria.
Artemisinin-based combination therapies have contributed to 
lower mortality rates, but, unfortunately, decreased clinical effica-
cy of artemisinin derivatives has already been reported in South-
east Asia [3]. Due to the ability of the mutated parasite to employ 
a quiescence mechanism, it is able to survive the short exposition 
time to dihydroartemisinin (DHA), the active metabolite of arte-
misinin, which has a short half-life, resulting in a slower rate of par-
asite clearance and recrudescence in patients [4].
Natural products have an incalculable therapeutic potential for 
antimalarial drug discovery. The source of many currently used 
drugs is inspired or directly derived from nature [5]. Poupartones 
are alkyl cyclohexenones derivatives isolated from the leaves of 
Poupartia borbonica Gmel. Previous studies showed the antimalar-
ial potential of this kind of compound. Poupartones are highly ac-
tive against P. falciparum, and previous in vivo studies on mice 
showed a growth inhibition of 69.5 % at day 7 post-infection at 15 
mg/kg/day [6]. Unfortunately, even if the mice treated showed a 
decrease in parasitemia, they died prematurely. A preliminary test-
ing on zebrafish larva demonstrated high contact toxicity as well 
as hints of cardiac toxicity, observed by a binocular microscope. For 
such compounds with promising activity, but potential toxicity, 
new drug delivery systems have to be developed with two main 
priorities: (1) to eliminate the parasite with maximum specificity 
and (2) to lower the adverse side effects of the drug compound.
iRBCs can be an interesting target for a controlled delivery sys-
tem. In fact, iRBCs are known to express proteins on their surface 
that are not expressed in non-infected RBCs, thus presenting them-
selves as targets. These protein complexes, called knobs, are pre-
sent in iRBC surfaces and allow effective cytoadhesion. This phe-
nomenon is important for the parasite’s survival, because it pre-
vents elimination by splenic clearance. iRBC sequestration appears 
after 16–20 h post-invasion, when iRBCs are able to display these 
adhesive properties. Because iRBCs are sequestered in different or-
gans, such as the brain and the lung, it leads to multiple problems, 
including hypoxia, hypoglycemia, and microvascular dysfunctions 
resulting in severe malaria, as mentioned previously [7]. The knob 
contains different proteins, including P. falciparum erythrocyte 
membrane 1 (PfEMP1) proteins, responsible for the adhesion phe-
nomenon resulting in the rosetting of iRBCs [8].
Glycosaminoglycans, like heparin, are able to inhibit PfEMP1 
proteins and, in this way, could prevent rosetting. Furthermore, its 
ability to bind this specific erythrocyte membrane protein consti-
tutes a good opportunity for the targeting strategy of nanocarri-
ers [9, 10]. Heparin is also able to bind parasite proteins, such as 
the circumsporozoite (CS) protein. The CS protein is present on the 
sporozoites’ and merozoites’ cell surface and plays a role in hepat-
ocyte invasion [11]. This approach represents a two-in-one oppor-
tunity to improve the efficiency of a targeting approach strategy, 
which was exploited with success by Marques et al. [10] in the de-
velopment of liposomes loaded with chloroquine and coated with 
heparin.
Liposomes are small vesicles made of concentric spheres of li-
pids. They are biocompatible and allow for the controlled release 
of both hydrophilic and hydrophobic drugs. Compared to other na-
noparticle systems, they demonstrated better capability to en-
hance the selectivity index of drugs by prolonging systemic circu-
lation time and minimizing toxicity and immunogenicity [12]. 
In vivo assays performed with liposomes of artemisinin demonstrat-
ed a much longer blood circulation time than free artemisinin [13], 
hence demonstrating a good strategy for the development of ther-
apeutics to treat parasitic diseases. Because this approach is very 
advantageous, several liposome formulations have been developed 
for malaria treatment, such as enclosing curcuminoids, chloro-
quine, and artemisinin derivatives, among others, which are de-
scribed in the review of Aditya et al. [14].
Consequently, this strategy was applied to poupartone B, which 
revealed high antiplasmodial activity, but also toxicity, in previous 
studies [15]. This compound was selected because of the high bio-
active potential of this class of compounds, which can be demon-
strated further through nanocarrier technology. Indeed, the alkyl 
cyclohexanone derivatives isolated from some Anacardiaceae, such 
as Lannea rivae, Lannea welwitshii, Lannea edulis, Taparira guianen-
sis, Taparira obtuse, and, more recently, from the mushroom Hygro-
phorus abieticola, demonstrated antimalarial, antibacterial, fungi-
cidal, and anticancer activities [15–19]. The aim of this study was 
to demonstrate the applicability of this formulation in the delivery 
of an isolated natural compound while minimizing its toxicity and 
improving its selectivity index, even on a partially artemisinin-re-
sistant strain.
Results and Discussion
Liposome formulations combined with poupartone B (1.0 mg for 
20.0 mM lipids) and 100 µg/mL heparin presented the most inter-
esting parameters in terms of size, charge, and polydispersity index 
(PDI). The liposome size was 183  ±  22 nm and 256  ±  20 nm before 
and after heparin addition, respectively, LSA revealing a size aug-
mentation due to the heparin attachment. The PDI was lower than 
0.1 and, as a result, suitable for medical use [20]. The zeta poten-
tial was 16.6  ±  1.7 mV before the addition of heparin and decreased 
to 11.8  ±  1.4 mV after heparin electrostatic bonding. The fact that 
the charge remained positive, making this a cationic liposome, is 
an advantage, because these are preferably endocytosed by tar-
geted cells as they are more attracted by the negatively charged 
cell membrane, improving the cellular concentration of the mole-
cule of interest [20, 21].
The pre-validation of the analytical procedure allows for verify-
ing the method’s ability to accurately quantify poupartone B in the 
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liposome formulation. Linearity, trueness, precision, accuracy, limit 
of detection (LOD), and limit of quantification (LOQ) [22] were eval-
uated and are presented in ▶Table 1.
The accuracy acceptance limits were set at 15 %, as per usual for 
isolated natural compounds. The upper and lower β-expectation 
tolerance limits never exceeded the acceptance limits (▶Fig. 1). 
Considering these results, the HPLC method was found to fulfill its 
objective, that is the accurate quantification of poupartone B in the 
liposomal matrix.
Liposomes were diluted ten times before injection in HPLC. 
Using a calibration curve, the formulation was found to contain 
304  ±  3 µg/mL (797.46  ±  8 µM) of poupartone B in the 20 mM of 
liposomes. The high activity of the compound allows for the use of 
a low concentration of product.
Heparin quantification
The quantification of heparin on the liposomes surface was per-
formed indirectly, since the quantity incorporated was below the 
detection limit of several tested techniques. The alcian blue meth-
od [23] was tested, but it was not sensitive enough to obtain re-
peatable results. Hence, the method used was 1H NMR performed 
on the lyophilized supernatants, which contained the heparin that 
was not incorporated in the liposome formulation. Maleic acid so-
lution 5 mM in D2O was used as a reference. The signal around 1.9 
ppm is the proton signal from the acetyl group of the sugars in the 
heparin molecule. Through the integration of the maleic acid and 
the control of heparin, the average percentage of heparin was 
25.78  ±  0.63 %. This corresponds to 25.78 µg of heparin on the li-
posomes surfaces (20 mM total lipids, 0.80 mM poupartone B) dis-
persed in 1.0 mL of PBS. Considering the IC50 of poupartone B (1.81 µM) 
[15], this quantity is thought to be adequate, as it stays within the 
interval of concentrations used by Marques et al. for targeting ac-
tivities [10].
The formulation with poupartone B and heparin tends to be 
more active than the free poupartone B, both on the chloroquine-
sensitive strain 3D7 as on the artemisinin partially resistant strain 
IPC 3445 (▶Table 2).
This trend suggests liposome intracellular delivery of poupar-
tone B to the iRBCs and that the improvement is due to the hepa-
rin. The decrease of toxicity on nonvascular human HeLa cells, 
which were used previously to highlight the toxicity of poupar-
tone’s compounds [15], reinforces the idea that this improvement 
of activity only occurred on iRBCs, and thus confirmed the applica-
bility of heparin as a targeting ligand to iRBCs. These elements to-
gether are encouraging, increasing the selectivity index from two 
times (on IPC strain) to three times (on 3D7 strain) for the poupar-
tone B/heparin liposome formulation. The formulation could be a 
good solution to avoid the compounds inherent toxicity.
Prolonged parasite clearance times with artemisinin derivatives 
were reported in Southeast Asia, suggesting the presence of an ar-
temisinin resistance phenotype [3]. It was observed that the ring-
stage parasites were able to develop a quiescent state, which was 
associated with a mutation in the Kelch 13 propeller domain [3]. In 
reality, the use of conventional in vitro methods to evaluate the IC50 
of drugs cannot discriminate an artemisinin partially resistant strain 
from a susceptible one after exposure to DHA, the active metabo-
lite [24]. In order to correlate survival of parasites in vitro with the 
time of parasitic clearance observable in vivo, the ring-stage sur-
vival assay [25] was used where a short pulse of DHA treatment 
during the early ring stage of the erythrocyte phase allows for ob-
serving differences in susceptibility between the sensitive and re-
sistant strain [25]. Synchronized young ring parasites were exposed 
to drugs during 6 h in correlation to the DHA’s half-life. After the 
washing step, they were grown in medium for 66 h to evaluate re-
crudescence. The parasitic growth was assessed by microscopic 
analysis. The rate of parasite survival exposed to DHA, poupartone B, 
and the formulation containing poupartone B with heparin is shown 
in ▶Fig. 2.
Poupartone B and the formulation were tested at the same con-
centration, corresponding to the IC50 of poupartone B, as estab-
▶Table 1 Pre-validation results (k =  number of series; n =  number of 
replicates per series).
Trueness (µg/mL) 
(k = 2, n = 3)





Slope 1.502 ; 1.513
Intercept −2.946 ; −4.131
r² 0.9920 ; 0.9994
Precision repeatability rsD ( %) Intermediate 






▶Fig 1 Accuracy profile obtained considering a linear regression 
for poupartone B; plain line: relative bias, dashed lines: β-expectation 
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lished by a conventional method, of 1 µg/mL (2.6 µM). This way, 
approximately half of the parasite’s population survives, and the 
test is able to establish the difference of survivability of the Plasmo-
dium artemisinin partially resistant strain between the free poupar-
tone B and the formulation.
The formulation showed an approximately 1.6-fold increase in 
potency compared to poupartone B alone, supporting the fact that 
the liposome’s formulation is able to improve the activity by con-
centrating poupartone B in red blood cells rapidly. As a whole, these 
results encourage further investigation, considering the liposomal 
system is able to deliver the compound in a short pulse time ( <  6 h). 
DHA was used as a control, and confirmed the partial resistance of 
the strain, as the survival rate was evaluated at 28  ±  3.5 %.
The zebrafish embryo acute toxicity test was used to observe 
the reduction of toxicity obtained by the nanovectorization. Ze-
brafish embryo and larvae are easily obtained in high quantities, 
and the transparency of the embryos and the possibility to use the 
mutant’s fluorescent embryos are convenient for investigating the 
causes of toxicity. Even if this model cannot replace rodents, it is 
very useful to qualitatively compare the toxicity of drugs in the early 
stages of research. Poupartone B and the liposome formulation 
were tested, and the petri dishes were observed at 24, 48, and 72 h 
post-fertilization (▶Fig. 3), after the first treatment administra-
tion. At the 24 h mark, both populations were alive.
The survival rate at 10 and 5 µg/mL exposure concentrations 
differ greatly between the poupartone B and the formulation. With 
5 µg/mL poupartone B, half of the larvae were dead at 72 h, which 
accounts for an LC50 of 5 µg/mL. With 10 µg/mL the liposome’s for-
mulation, only 2 larvae died, thus the LC50 was set between 10 and 
15 µg/mL. At the end of the test, with 10 µg/mL of exposure con-
centration, more than 80 % of the larvae were alive with the formu-
lation while only 10 % survived with the compound alone, which 
accounts for a major difference in survivability. All the population 
died at an exposure concentration of 15 µg/mL, which confirms the 
lethality of this dose, as previously highlighted [15]. Even if the sur-
vival rate was improved with the formulation, morphological alter-
ations, such as the disappearance of somite, necrosis in the tail, 
smaller size, cardiac toxicity, and abnormal movements of the lar-
vae, once outside the chorion, were observed by binocular micros-
copy in both populations, at the same degree.
In this study, a targeted nanovectorization approach based on 
the results of Marques et al. [10] was tested for the administration 
of a natural antimalarial cytotoxic compound, poupartone B. The 
results show a decrease of toxicity and an improvement in effec-
tiveness. The RSA0-3 h, which is able to predict the potency of com-
pounds against artemisinin-resistant parasites in malaria patients 
[24], demonstrated the potent activity of the heparin-targeted li-
posomes towards an artemisinin-resistant isolate compared to 
poupartone B alone. Furthermore, it confirmed that this formula-
tion was able to kill resistant parasites, even with a short contact 
time. These results pave the way for further investigations on lipo-
some formulation applied to alkyl cyclohexenone derivatives in the 
context of the DHA partial resistance observed in Asia. Cytotoxic-
ity tests confirmed the decrease of toxicity by the formulation in 
both HeLa cells in vitro and in the zebrafish embryos model. Li-
posomes had already demonstrated their potential to decreased 
▶Fig. 2 Survival rate of parasites in the RSA test ( %) with a treat-
ment dose of 2.6 µM poupartone B and liposomes containing 2.6 µM 



















▶Table 2 Antiplasmodial and cytotoxic activities of poupartone B, empty liposomes, and liposomes containing poupartone B with or without heparin.
samples P. falciparum IC50 (µg/mL) 
(n  =  3) 3D7 IPC 3445 
Cytotoxicity IC50  
(µg/mL) (n  =  2) HeLa 
selectivity index 
HeLa/3D7 HeLa/IPC 3445 
Hemolysis ( %) 
Poupartone B 0.69  ±  0.20
0.40  ±  0.15
1.44  ±  0.34 2.09
3.60
 <  1 %
Formulation without poupartone B NA
NA
NA NA  <  1 %
Formulation poupartone B- liposome without 
heparin addition
0.86  ±  0.26
0.61  ±  0.19
3.88  ±  0.60 *  * 4.51
6.36
 <  1 %
Formulation poupartone B- liposome added 
with 1.3 µg heparin/mM liposome lipids 
0.41  ±  0.01 * 
0.35  ±  0.08
2.52  ±  0.02 *  * 6.15
7.20
 <  1 %
Artemisinin 0.004  ±  0.001 NT - NT
Doxorubicin NT 0.085  ±  0.055 - NT
NA  =  non-active; NT  =  not treated.  * P value  <  0.05 compared to the administration of the formulation without heparin;  *  * p value  <  0.02 compared to 
the administration of poupartone B without any formulation.
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toxicity and improve effectiveness, and heparin has been highlight-
ed for its ability to target iRBCs. This study contributes to highlight-
ing the benefit of the combination of these strategies in terms of 
activity, especially against partially resistant P. falciparum strains. 
These approaches could represent an important advantage since 
the emergence of artemisinin resistance has become a major pub-
lic health problem. This work also emphasizes the interest of an un-
derstudied class of natural compounds, the alkyl cyclohexanone 
derivatives, as potential bioactive substances. Objectively, even if 
poupartone B is too toxic to be a good candidate for becoming an 
antimalarial drug, this class of compound should be investigated 
in more depth, since it isn’t clear the mechanism of action through 
which the compounds exert both antiplasmodial activity and tox-
icity. At this moment, the structure-activity relationship has not 
been not clearly established. However, some hypotheses can be 
proposed considering the data present in the literature. It seems 
that this bioactive class of compounds frequently presents a ketone 
function [16, 18, 19, 26], and the toxicity appears to be related to 
the number of oxygen atoms. Some compounds of this group that 
demonstrated high bioactivities, without in vitro toxicity, contain 
less oxygen atoms than the others [26, 27]. Thus, poupartone B can 
be a good precursor for semisynthetic compounds with higher ther-
apeutic potential and selectivity.
The discussed data indicates that a heparin-targeted nanovec-
torization system is efficient and could be successfully applied 
against artemisinin-resistant P. falciparum. Furthermore, the eryth-
rocytic stage of malaria was the exclusive phase investigated. Other 
studies have demonstrated that heparin can also target different 
P. falciparum stages, such as the sexual stage in mosquitoes. This 
might pave the way for multiple approaches to proceed with these 
studies.
Nanotechnology will be a key player in the fight against the oc-
currence of drugs resistance, especially in the field of malaria, where 
new treatments are urgently needed.
Materials and Methods
General experimental procedures
Except where otherwise indicated, all lipid materials were pur-
chased from Avanti Polar Lipids and all reagents were purchased 
from Sigma-Aldrich. Poupartone B was isolated from the leaves of 
male plants of P. borbonica, as previously described by our team 
(purity  >  98 % according to HPLC analysis) [15]. This anacardiace-
ae was collected in Langevin, Reunion Island, in June 2018 and iden-
tified by Hermann Thomas (Parc National de La Réunion). Voucher 
specimens (no. RUN 028F, TCN-P022F) were deposited in the Her-
barium of the University of Reunion Island.
Liposomes preparation
Liposomes were prepared by the lipid film hydration method [28]. 
Different formulations (with and without bounded heparin) were 
performed based on the protocol described by Marques et al. [10]. 
Briefly, lipids (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylam-
monium methyl-sulfate, DOTAP (4 % molar), 1,2-dioleoyl-sn-glyc-
ero-3-phosphocholine, DOPC (76 % molar), and cholesterol (20 % 
molar) (ovine wool,  >  98 %) were dissolved with poupartone B in 
chloroform (20 mM total lipids with a poupartone B concentration 
of 2.6 mM). The organic solvent was removed by rotary evapora-
tion under reduced pressure at 37 °C to yield a lipid film. The film 
was hydrated with 1.0 mL PBS (pH 7.4). Liposomes were formed by 
vortexing and downsized by extrusion through polycarbonate 
membranes (5 times on 400 nm, 3 times on 200 nm, and 3 times 
on 100 nm). Liposomes were purified 3 times by ultracentrifuga-
tion at 35 000 rpm at 4 °C during 2 h by cycle (Beckman Coulter, 
Optima L-90K). Heparin was electrostatically bound to cationic li-
posomes by the addition of proportional 100–150 µg heparin/mL 
PBS for 20 mM of lipid liposome preparation containing 4 % DOTAP. 
The unbound heparin was removed by ultracentrifugation with the 
same conditions described for the purification and all supernatants 
were collected for NMR quantification. Liposomes size, PDI, and 
zeta potential were obtained by a dynamic light scattering technic 
▶Fig. 3 Survival ( %) of the zebrafish at 48 and 72 h exposure to the control (DMSO 0.01 %), liposomes containing heparin without poupartone B 
(empty liposome), a concentration range (1–15 µg/mL) of poupartone B (1–15 µg/mL), and liposomes containing the same quantity of poupartone 
B with heparin (1–15 µg/mL).
0
DMSO 0.01 % Empty
liposome
1 µg/mL 5 µg/mL 10 µg/mL 15 µg/mL DMSO 0.01 % Empty
liposome
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using Malvern Zetasizer (Nano ZS; Malvern Instruments). Encapsu-
lated poupartone B was quantified by an HPLC-DAD method. Ex-
cept where otherwise indicated, the term “formulation” is used to 
designate the liposomes containing poupartone B and bounded 
heparin.
Poupartone B quantification
Analytical HPLC was carried out on an Agilent 1100 Series at a flow 
rate of 1 mL/min. An RP select B LiChrospher 60 (250  ×  4.6 mm) 
column was chosen. A mobile phase composed of formic acid 0.1 % 
in water and methanol was used in a gradient elution (40:60 to 
0:100 v/v in 30 min). The UV-Vis detector was set at 254 nm. The 
HPLC-DAD method was validated. The following criteria were in-
vestigated: linearity, trueness, precision, accuracy, LOD, and LOQ. 
Pre-validation of the method was performed on two series with 
three independent replicates at three concentrations (20, 50, and 
100 µg in the presence of 20 mM lipids such as in the liposome 
preparation) over a period of 2 days. Data processing was per-
formed with Enoval 4.1 software.
When the formulation was analyzed, a calibration curve was per-
formed for each quantification. Liposomes were diluted 10 times 
in MeOH and destroyed by ultra-sonication before being injected 
into HPLC for poupartone B quantification.
Heparin NMR quantification
1H NMR spectra were recorded in D2O on a Bruker Avance spec-
trometer operating at 500.13 MHz equipped with a cryoprobe. Ma-
leic acid (purity  >  99 %; Sigma-Aldrich) was used as an internal 
standard for 1D experiment quantification. All spectra were cali-
brated with internal sodium 3-trimethylsilyl-2,2,3,3-d4-propion-
ate at the 0.00 ppm chemical shift. All the supernatants collected 
during the liposome preparation were gathered and lyophilized. 
The lyophilizate was dissolved in D2O, and 700 µL of this solution 
were taken to quantify the heparin that had not bound to the li-
posomes. The amount of heparin bound to the liposomes was de-
duced by the difference between what was initially introduced and 
what was not bound.
In vitro antiplasmodial activities
Continuous in vitro cultures of asexual erythrocyte stages of P. fal-
ciparum, chloroquine-sensitive strain 3D7 (originally isolated from 
a patient living near Schipol airport in the Netherlands) [29], and 
artemisinin partially resistant strain IPC 3445 (originally isolated 
from a patient in western Cambodia in 2010) [30] were maintained 
following the procedure of Trager and Jensen [31]. Strains were ob-
tained from ATCC, Bei Resources. The host cells were human red 
blood cells (A + ). The culture medium comprised RPMI 1640 (Gibco, 
Fisher Scientific) containing NaHCO3 (32 mM), HEPES (25 mM), and 
L-glutamine. The medium was supplemented with 1.76 g/L of glu-
cose (Sigma-Aldrich), 44 mg/mL of hypoxanthine (Sigma-Aldrich), 
100 mg/L of gentamycin (Gibco, Fisher Scientific), and 10 % human 
pooled serum (A + ), as previously described [6, 15].
Liposome solutions were directly diluted in the medium; each 
test sample was applied in a series of eight 2-fold dilutions in a 
96-well plate and tested in triplicate (concentration tested was cal-
culated in µg/mL of poupartone B). The parasitemia was 2 %, and 
the hematocrit was 1 %, as previously described [32]. Parasite 
growth was estimated after 48 h incubation by the determination 
of lactate dehydrogenase activity, according to the methods de-
scribed by Makler et al. [33]. Artemisinin (purity  >  98 %; Sigma-Al-
drich) at an initial concentration of 100 ng/mL was used as positive 
control in all experiments. IC50 (half-maximal inhibitory concentra-
tion) values were calculated from sigmoidal curves.
Ring-stage survival assay (0–3 h)
Ring-stage survival assays were performed on artemisinin partial-
ly resistant strain IPC 3445 as previously described by Witkowski 
et al. [25] and Baumgärtner et al. [24].
Briefly, 0–3 h post-invasion ring stages were adjusted to 2 % he-
matocrit and 1 % parasitemia. Of this solution, 900 µL were added 
to 100 µL of solutions containing DHA (700 nM) (purity  >  97 %; Sig-
ma-Aldrich), poupartone B (2.6 µM), or liposome formulation (2.6 
µM of poupartone B). Tests were performed in 48-well plates and 
exposed for 6 h. Afterwards, cultures were transferred to 15 mL 
tubes and were centrifuged at 800 g for 5 min. The blood pellets 
were dispersed in medium (10 mL) in a cleaning step. After remov-
ing the drug, the red blood cells were dispersed with 1 mL of cul-
ture media. They were transferred to new wells for a 66-h incuba-
tion period. The survival percentage was established by comparing 
the number of viable iRBCs after explosion in thin blood smears to 
that of the drug-free DMSO incubation.
In vitro cytotoxic activity
Assays were performed on HeLa cells to evaluate the cytotoxicity 
potential of the formulation and the compound alone. Compounds 
were tested in 96-well microplates using the tetrazolium salt WST-1 
(Roche Diagnostics Belgium) colorimetric assay based on the cleav-
age of the reagent by mitochondrial succinate-tetrazolium reduc-
tase in living cells. Tests were performed as previously described 
[15]. Briefly, cells were seeded 6000 per well in 200 µL of medium 
supplemented with adequate concentrations of the tested drugs. 
After 48 h of incubation, 10 µL of WST-1 were added to each well. 
After 30 min at 37 °C, the plates were shaken, and absorbance val-
ues were recorded at 450 nm. The absorbance values were ex-
pressed in percentage terms compared to untreated control cells. 
IC50 values were calculated from graphs. The HeLa cells were ob-
tained from the Laboratory of Medical Chemistry, GIGA, ULg.
In vitro hemolytic activity
A red blood cell suspension [A + , 10 % in PBS (v/ v)] was incubated 
with poupartone B and liposomal formulation in triplicate. The final 
concentration was 5 μg/mL for poupartone B (with and without for-
mulation) and the corresponding formulation without the active 
compound. After agitation at room temperature for 1 h, the tubes 
were centrifuged for 5 min at 2000 rpm, and 150 μL of each super-
natant were transferred to a 96-microwell plate to measure the ab-
sorbance (OD) at 550 nm with a microplate reader. The positive 
control was Triton X-100 1 % (v/v) and PBS as the negative control. 
The percentage of red blood cell lysis (H) was calculated as follows: 
H  =  (OD550 nm sample  −  OD550 nm PBS)/(OD550 nm Triton 
X-100 1 % (v/v)  −  OD550 nm PBS), as previously described [15].
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Selectivity index
The selectivity index was obtained as the ratio of IC50 between the 
cytotoxic activity on HeLa cells and 3D7 or IPC 3445 parasitic ac-
tivities, respectively.
Zebrafish embryos acute toxicity test
Adult zebrafish (Danio rerio) were maintained while fulfilling the 
criteria of the Ethical Committee for the Use of Laboratory Animals 
at the University of Liège. They were maintained at 28 °C on a 14-h 
day/10-h night period, and fertilized eggs were collected, washed 
with sterile water, and placed in petri dishes. Embryos were collect-
ed, and their chorions were not removed. Previously, in another 
study, our team determined the LC50 (half-maximal lethal exposure 
concentration) for poupartones [15]. Consequently, the narrower 
geometric series was performed without first carrying out the log-
arithmic concentrations series test [34] to avoid wasting fish use-
lessly.
Poupartone B was dissolved in DMSO solution and was diluted 
with the medium used for the zebrafish. The exposure concentra-
tions of poupartone B were between 1 and 15 µg/mL, both individ-
ually and in the formulation, with full knowledge from previous 
studies that at a concentration of 15 µg/mL of the compound is 
completely lethal in the zebrafish model [15]. The DMSO’s final 
highest concentration was 0.4 %. The liposome formulations were 
directly dissolved in the medium used for zebrafish. Twenty em-
bryos were used per condition in a 6-well plate. Each well contained 
5 mL of the treatment dose, which was replaced once daily for 
3 days. The embryos were observed each day until 72 h post-ferti-
lization. Wells with 20 embryos were used as the control for the 
solvent (DMSO, 0.4 %), the formulation (liposome  +  heparin), and 
poupartone B at 15 µg/mL.
Statistical analysis
Statistical significance between the compound and the formula-
tion was set at p  <  0.05 and analyzed with Student’s t-test in Graph-
Pad Prism.
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